Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STAR-0310 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| STAR-0310 Dose 1 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 2 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 3 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 4 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 in Participants of Japanese Descent | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| Name | Type | Description |
|---|---|---|
| STAR-0310 | DRUG | STAR-0310 will be administered as a subcutaneous bolus injection. |
| Placebo | DRUG | Placebo will be administered as a subcutaneous bolus injection. |
Inclusion Criteria: * Good health as determined by the Investigator based upon a medical evaluation. * Body mass index (BMI) of 18 to 35 kg/m2 with a weight of at least 60 kg for men and at least 50 kg for women, with a maximum weight of 130 kg for any participant. * Participants of childbearing po...
STAR-0310 is an investigational small molecule being developed by Astria Therapeutics, Inc. It is in Phase 1 clinical development and is designed to target OX40. The program is currently being evaluated in healthy adult volunteers rather than in a specific patient population.
STAR-0310 targets OX40, a protein target. OX40 is a receptor expressed on activated T cells and is studied as a costimulatory immune target. Astria Therapeutics is developing STAR-0310 as a small molecule directed at OX40, and the Phase 1 program is evaluating it in healthy adult participants.
STAR-0310 is being developed by Astria Therapeutics, Inc., which trades on the Nasdaq under the ticker ATXS. The company is the sponsor of the Phase 1 study of STAR-0310 in healthy adult participants in the United States.
STAR-0310 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Astria Therapeutics is running a single Phase 1 study of STAR-0310, which is currently active but no longer recruiting participants.
STAR-0310 is being studied in one Phase 1 trial, NCT06782477, titled A Study of STAR-0310 in Healthy Adult Participants. The trial is active but not recruiting, is randomized, double blind, and controlled, and plans to enroll 40 healthy adult volunteers in the United States.
Yes. The Phase 1 trial of STAR-0310, NCT06782477, enrolls healthy adult participants rather than patients with a specific disease. It is a randomized, double blind, controlled study of 40 participants aged 18 years and older, conducted in the United States, and it is currently active but not recruiting.